Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity-Weighted Cohort StudyJOURNAL OF THE AMERICAN HEART ASSOCIATIONIF5.32019-06-0441OAAI
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral HemorrhageSTROKEIF8.92019-04-0140OAAI
Risk of recurrence and bleeding with Rivaroxaban among patients with venous thromboembolism and active cancerTHROMBOSIS RESEARCHIF3.42018-04-010PREAI
Bleeding Complications in Anticoagulated Patients With Atrial Fibrillation and Sepsis: A Propensity-Weighted Cohort StudyJOURNAL OF THE AMERICAN HEART ASSOCIATIONIF5.32017-11-017OAAI
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor A Nationwide Cohort StudyJAMA CARDIOLOGYIF14.12017-08-0143OAAI
Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort studyLANCET HAEMATOLOGYIF17.72017-05-0140PREAI
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort studyBMJ-BRITISH MEDICAL JOURNALIF42.72017-02-10260OAAI
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort studyBMJ-BRITISH MEDICAL JOURNALIF42.72016-06-16364OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向